CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
a study on Lung Cancer Non-Small Cell Lung Cancer Kidney Cancer Colorectal Cancer Breast Cancer Cervical Cancer Ovarian Cancer Pancreatic Cancer Endometrial Cancer Sarcoma Head and Neck Cancer Head and Neck Squamous Cell Carcinoma Squamous Cell Carcinoma Bladder Cancer Metastatic Castration-Resistant Prostate Cancer Prostate Cancer Hodgkin's Lymphoma Lymphoma Non Hodgkin Lymphoma
Non-Small Cell Lung Cancer Renal Cell Cancer Colorectal Cancer Triple Negative Breast Cancer Cervical Cancer Ovarian Cancer Pancreatic Cancer Endometrial Cancer Sarcoma Squamous Cell Carcinoma of the Head and Neck Bladder Cancer Metastatic Castration Resistant Prostate Cancer Non-hodgkin Lymphoma NSCLC RCC TNBC mCRPC CRC Lung Cancer Kidney Cancer Rectal Cancer Breast Cancer Endometrial Pancreatic Ovarian SCCHN NHL Endometrial Neoplasms Triple Negative Breast Neoplasms Carcinoma, Renal Cell Squamous Cell Carcinoma of Head and Neck Pembrolizumab CPI-006 CPI-006 + ciforadenant CPI-006 + pembrolizumab Cohort1b
Lead Scientist at UC Cancer
- Lawrence Fong (ucsf)
Lawrence Fong, M.D. is the Efim Guzik Distinguished Professor in Cancer Biology in the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, where he leads the Cancer Immunotherapy Program. He also co-directs the Parker Institute of Cancer Immunotherapy at UCSF and co-leads the Cancer Immunity and Immunotherapy Program in the Cancer Center.
- accepting new patients
- Start Date
- Completion Date
- Corvus Pharmaceuticals, Inc.
- Phase 1 research study
- Study Type
- Expecting 378 study participants
- Last Updated